Clinical trials: Neoplasm, Brain
Brain Metastases
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
This trial is a pilot, Phase 2, sequential two-cohort study designed to test two de-escalated whole brain radiation therapy (WBRT) dose levels and assess their ability to maintain acceptable in-brain distant control.
- Trial name
- NCT03189381
- Testing
- Cohort A, Cohort B
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Brain and Central Nervous System Tumors
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00337207
- Testing
- bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Northwestern University
Cognitive Dysfunction, Dementia, Mild
FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease
This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
- Trial name
- NCT05504811
- Testing
- FitMi AD, Conventional exercise program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Chronic Disease, Frail
Functional Exercise and Nutrition Education Program for Older Adults
There is strong evidence that specific types of exercise can improve health and physical function in older adults. While community exercise classes exist, many older adults with chronic conditions may need guidance from…
- Conditions
- Chronic Disease, Frail, Diabetes Mellitus, Cancer
- Trial name
- MoveStrong (NCT04037436)
- Testing
- Strength and Balance Training & Nutrition Education, Usual Care
- Where
- 5 sites in Canada
- Volunteers
- 44 people
- Sponsor
- University of Waterloo
Glioblastoma, Cancer of Brain
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks…
- Conditions
- Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor
- Trial name
- NCT03705351
- Testing
- Tumor Treating Fields, Temozolomide, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Providence Health & Services
Brain Cancer
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
- Trial name
- NCT01105702
- Testing
- Temozolomide, Bevacizumab, Lithium Carbonate
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced solid tumors (Phase 1) and subjects with…
- Trial name
- NCT02765165
- Testing
- USL311, Lomustine
- Where
- 6 sites in United States, Spain
- Volunteers
- 26 people
- Sponsor
- Proximagen, LLC
Adult Glioblastoma, Depression
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
This clinical trial is studying magnetic resonance spectroscopy imaging in predicting response in patients to vorinostat and temozolomide in patients with recurrent, progressive, or newly diagnosed glioblastoma.
- Conditions
- Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
- Trial name
- NCT01342757
- Testing
- vorinostat, temozolomide, magnetic resonance spectroscopic imaging
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasms
FLT-PET Imaging of Brain Tumors in Children
Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is important in the management of these tumors, but current imaging methods have limitations in providing the necessary information for…
- Trial name
- NCT01244737
- Testing
- [18F] FLT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Frederick Daniel Grant
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- GRABM-L (NCT01497665)
- Testing
- GRN1005
- Where
- 10 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Angiochem Inc
Brain Metastases, Small Cell Lung Cancer
Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain
This study is a prospective single arm trial designed to study the safety and effectiveness of a medical device, NovoTTF-200A, used with stereotactic radiosurgery (SRS) in subjects with brain metastases from small cell lung…
- Trial name
- RAD 1704 (NCT03488472)
- Testing
- NovoTTF-200A, Stereotactic Radiosurgery (SRS)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Drexell Hunter Boggs
Malignant Glioma
Lerapolturev in Recurrent Malignant Glioma
This is a phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma.
- Trial name
- NCT02986178
- Testing
- lerapolturev, Lomustine
- Where
- 6 sites in United States
- Volunteers
- 121 people
- Sponsor
- Istari Oncology, Inc.
Metastatic Melanoma, Brain Metastases
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain.
- Trial name
- EBRAIN-MEL (NCT03898908)
- Testing
- encorafenib, binimetinib, Whole brain radiation therapy
- Where
- 21 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Brain Tumors With Ill-defined Margins
Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection
The purpose of this study is to investigate whether stereotactic indigo carmine injection can safely increase the extent of tumor resection.
- Trial name
- NCT01767415
- Testing
- Indigo carmine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Weill Medical College of Cornell University
Brain Metastases From Non-small Cell Lung Cancer
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT01657799
- Testing
- Veliparib, Whole brain radiation therapy
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Liver Metastases, Lung Metastases
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic).
- Conditions
- Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT02107755
- Testing
- ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Intractable Epilepsy, Malignant Glioma
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
This phase IV trial studies the side effects and how well perampanel works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy. Perampanel is a drug used to treat seizures.
- Conditions
- Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma
- Trial name
- NCT04650204
- Testing
- Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
BRAFV600E Melanoma Patients
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
The purpose of this study is to test the safety and find out what effects, good and/or bad, dabrafenib (a BRAF inhibitor) alone or dabrafenib when given in combination with gamma knife radiosurgery has on participants with a…
- Trial name
- NCT01721603
- Testing
- Dabrafenib, Gamma Knife Radiosurgery, Trametinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma
- Trial name
- NCT00112736
- Testing
- erlotinib, temsirolimus, therapeutic conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
Phase I/II trial to estimate the maximum tolerated dose of imatinib mesylate in newly diagnosed brain stem gliomas and recurrent high grade gliomas and to assess the effectiveness of imatinib mesylate in treating young patients…
- Trial name
- NCT00021229
- Testing
- imatinib mesylate, local irradiation therapy
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)